Clinical Trial: PCV21 Acceptance in Adults >=50 Years and Caregivers in Panama

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809113) titled 'PCV21 Acceptance in Adults >=50 Years and Caregivers in Panama' on Sept. 02.

Brief Summary: This study will look at what adults age 50 years and older in Panama know, think, and do about pneumococcal vaccination, including the 21-valent pneumococcal conjugate vaccine (PCV21). Pneumococcal disease can cause pneumonia and other serious infections, and older adults may be at higher risk of severe illness. The study will help researchers understand what supports or prevents vaccine acceptance in this population.

The study will include two groups. Group A will include adults 50 to 64 years of age. Group B will include adults 65 years o...